RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013

30 oktober 2013 * Consolidated revenue € 702.0 million, + 13.2%. * EBITDA((1)) € 174.0 million, + 15.4% * Operating income € 148.3 million, + 12.0%. * Net income € 101.5 million, + 9.0%. * Net financial position((2)):  net debt of € 133.3 million. * Closing of the acquisition of a portfolio of drugs for the treatment of rare and other diseases in the U.S.A.. * Agreements signed for the acquisition of Opalia Pharma S.A., a Tunisian pharmaceutical company. * Acquisition of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company. Transaction closed in October. * Full year 2013 targets updated. * Interim 2013 dividend of € 0.22 per share to be distributed. Milan, 30 October 2013 - The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first nine months 2013 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website: http://www.recordati.com/rec_en/investors/reports/ and can also be viewed on the website of Borsa Italiana S.p.A. Financial highlights * Consolidated revenue in the first nine months 2013 is € 702.0 million, up by 13.2% compared to the same period of the preceding year. International sales grow by 16.5%. * EBITDA((1)), at 24.8% of sales, is € 174.0 million, an increase of 15.4% over the same period of the preceding year. * Operating income, at 21.1% of sales, is € 148.3 million, an increase of 12.0% over the same period of the preceding year. Included is an € 8.0 million provision covering the completion of the sales force reorganization in the French subsidiary. * Net income, at 14.5% of sales is € 101.5 million, an increase of 9.0% over the first nine months 2012. * Net financial position((2)) at 30 September 2013 records a net debt of € 133.3 million. During the period $ 100.0 million (€ 75.0 million) were paid for the acquisition of a portfolio of products for the treatment of rare and other diseases, sold mainly in the U.S.A., from Lundbeck LLC, and dividends were distributed for a total of € 20.1 million. Shareholders' equity increases to € 722.0 million. ((1)) Earnings before interest, taxes, depreciation and amortization. ((2) )Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge). Business development news In January the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck LLC. was successfully concluded. The value of the transaction is of $ 100 million, of which $ 80 million paid at the closing on January 18 and $ 20 million in August.  The acquired portfolio is now marketed in the U.S. by Recordati Rare Diseases Inc., a wholly-owned U.S. corporation. The main product in the portfolio is Panhematin® (haemin for injection) for the amelioration of recurrent attacks of acute intermittent porphyria. Other important drugs acquired are NeoProfen® (ibuprofen lysine injection), indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, and Cosmegen® (dactinomycin for injection) used mainly in the treatment of three rare cancers. During July the agreements covering the acquisition of 90% of the share capital of Opalia Pharma S.A., a Tunisian pharmaceutical company with headquarters in Ariana, a suburb of Tunis, were signed. The value of the transaction (enterprise value) is of around € 37 million and will be funded from existing liquidity. A partial closing of the transaction, involving the majority of the capital which is held by non-Tunisian shareholders, is expected to take place shortly. Opalia Pharma was established in 1988, ranks eighth in the Tunisian pharmaceutical market and is the third largest local pharmaceutical company. The company markets branded generic drugs with leading products in dermatology and in the gastrointestinal and respiratory therapeutic areas. Opalia manufactures most of its products in a modern, cGMP certified production facility specialized in liquid and semi-solid forms. The company employs around 320 people and generates annual sales of around TND 40 million (around € 18 million). During September the agreements covering the acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza, were signed. The transaction was successfully concluded in October. The value of the transaction (enterprise value) is of € 93 million of which € 89.5 million were paid at the closing. Casen Fleet primarily markets internally developed drugs principally in the gastroenterological therapeutic area in Spain and Portugal through its own organisation and in other countries through partners. Approximately 55% of revenue is generated by a line of products used in the preparation for colonoscopy. The main product in this line is Citrafleet®, already marketed by Recordati in Germany. The company's product portfolio also comprises oral rehydration products, probiotics and OTC brands for gynecological use. Approximately 80% of revenue is generated by private payers and is therefore outside public healthcare reimbursement schemes. Casen Fleet develops and manufactures most of its medicines in its own facility in Utebo, Zaragoza, which occupies an area of 23,165 sq. m. The company employs around 230 people and sales in 2012 are € 45.3 million. Subsequent events and business outlook During October the acquisition of 100% of the share capital of Laboratorios Casen Fleet S.L.U., a Spanish pharmaceutical company with headquarters in Madrid and production facilities in Utebo, Zaragoza, was successfully concluded. The value of the transaction (enterprise value) is of € 93 million of which € 89.5 million were paid at the closing. The group's business performance was in line with expectations during October. For the full year 2013, targets are to achieve sales of more than € 930 million, operating income of more than € 190 million and net income of more than € 132 million. Further resolutions 2013 Interim dividend The Board of Directors resolved to distribute an interim dividend relating to the financial year 2013 amounting to € 0.22 (before withholding tax) on each outstanding share, excluding shares in treasury stock. The interim dividend will be paid, through the authorised intermediaries, as from November 21, 2013 on coupon No. 12 to be presented on November 18, 2013. The Independent Auditor's opinion on the distribution of the interim dividend is also available at the Company's registered offices as per article 2433-bis of the Italian Civil Code. The Directors' Report and financial statements of Recordati S.p.A. as at 30 June 2013, on which the Board of Directors based its resolution to distribute the abovementioned interim dividend, are available at the Company's registered offices and published on the Company's website (www.recordati.com). Such documents may also be viewed on Borsa Italiana S.p.A.'s website. Stock options granted As per article 84-bis of Consob Regulation 11971/99 ("Issuers' Regulations") we furthermore inform that the Board of Directors, as proposed by the Remuneration Committee in its meeting of today, resolved to grant 360,000 stock options under the 2010-2013 Stock Option Plan approved by the Shareholders' Meeting of 13 April 2010, to 4 employees of Recordati S.p.A. and its subsidiaries (see table attached). The options may be exercised only if certain consolidated net income objectives are reached. The strike price, calculated by averaging the market price of the share over the period between the date of grant and the same day of the preceding month, is fixed at € 8.93 The characteristics of the plan are described in the information document issued on 5 March 2010 (the object of the third point of the Board's explanatory report on the 13 April 2010 Meeting's Agenda) and available on the company's website: http://www.recordati.it/investors/regulated_information/stock_options.aspx?sc_la ng=en Conference call Recordati will be hosting a conference call today 30 October 2013 at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The dial-in numbers are: Italy     +39 02 8058811, toll free 800 213 858 UK     +44 1 212818003, toll free 800 0156384 USA     +1 718 7058794, toll free 855 2656959 France     +33 170918703 Germany     +49 65 255114451 Callers are invited to dial-in 10 minutes before conference time.  If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371.  A recording of the conference call will be placed on the website www.recordati.com. A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations. Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of over 3,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey and in the United States of America.  A field force of more than 1,700 medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories.  Recordati is committed to the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases.  Consolidated revenue for 2012 was € 828.3 million, operating income was € 167.0 million and net income was € 118.5 million. For further information: Recordati website:  www.recordati.com Investor Relations                                 Media Relations Marianne Tatschke         Ketchum (39)0248787393                                Cristina Risciotti, (39)0262411919, cristina.risciotti@ketchum.com e-mail: inver@recordati.it                         Marzia Ongaretti, (39)0262411915, marzia.ongaretti@ketchum.com Statements contained in this release, other than historical facts, are "forward- looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance. RECORDATI REPORTS SIGNIFICANT GROWTH IN THE FIRST NINE MONTHS 2013: http://hugin.info/143644/R/1739235/583657.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: RECORDATI via Thomson Reuters ONE [HUG#1739235]